Handelsavisen
prelaunch
Companies ›Healthcare ›1951.HK
19
1951.HK — HKEX Healthcare Facilities & Services

Jinxin Fertility Group Ltd

HK$2,30
Open in Charts → Attach watcher ⌖
— —
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
6,2B HKD
P/E
—
EV / Rev
—
Div yield
1,75 %
Op margin
-34,9 %
ROE
-10,7 %
Net margin
-36,8 %
Debt / equity
0,32
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Jinxin Fertility Group Ltd provides fertility services and operates in the healthcare facilities and services industry, generating revenue primarily through medical treatments and procedures related to reproductive health.

Business. Jinxin Fertility Group Ltd (1951.HK) is a healthcare services company listed on the Hong Kong Stock Exchange. The firm operates within the Healthcare Facilities & Services industry, providing biotechnology-related medical services. Specific details regarding its operating segments, headquarters location, and geographic presence are not available in the provided data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
BUY12 analysts
8 buy2 hold2 sell
Avg 12m price target3,25

Analyst recommendations

12 analysts · consensus Buy
Buy8
Hold2
Sell2
12-month price target
3,25
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
12 analysts · indicative
Ownership
—
not yet wired
Profitability→
-10,7 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 1951.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 1951.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Jinxin Fertility Group Ltd (1951.HK) is a healthcare services company listed on the Hong Kong Stock Exchange. The firm operates within the Healthcare Facilities & Services industry, providing biotechnology-related medical services. Specific details regarding its operating segments, headquarters location, and geographic presence are not available in the provided data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    Jinxin Fertility Group Ltd has a market price of 2.23 CNY and a market capitalization of 6.03 billion CNY, with a price-to-book ratio of 0.66 and a price-to-tangible-book ratio of 0.66. The company's liquidity position is characterized by a current ratio of 0.87, indicating a moderate liquidity risk. The enterprise value to revenue ratio is 3.39, while the enterprise value to EBITDA ratio is negative at -9.73, reflecting the company's current operating losses.

    The company's profitability is underperforming, with a return on equity of -10.68% and a return on assets of -6.99%. These metrics are below the industry median for healthcare facilities and services, suggesting that Jinxin Fertility Group Ltd is not generating returns that meet the expectations of its sector. The company's operating income is negative at -923.52 million CNY, and its net income is also negative at -976.15 million CNY.

    Jinxin Fertility Group Ltd's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification increases the company's exposure to regional economic fluctuations and regulatory changes. The company's capital structure includes long-term debt of 2.96 billion CNY and total liabilities of 4.82 billion CNY, with total equity of 9.14 billion CNY.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the data. However, the company's operating cash flow is positive at 588.89 million CNY, while its free cash flow is negative at -902.33 million CNY. This suggests that the company is not generating sufficient cash from operations to cover its capital expenditures and other obligations.

    The risk assessment for Jinxin Fertility Group Ltd indicates a medium liquidity risk and a low dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could impact its ability to meet short-term obligations. The company's debt-to-equity ratio of 0.32 suggests a relatively conservative capital structure.

    Recent analyst estimates indicate a mean price target of 3.25 CNY and a median price target of 3.15 CNY, with a mean recommendation of 2.25 (1=strong buy, 5=strong sell). The company has received 3 strong-buy ratings, 5 buy ratings, and 2 hold ratings, suggesting a generally positive outlook from analysts.

    Key takeaways
    • Jinxin Fertility Group Ltd is a healthcare services provider with a market capitalization of 6.03 billion CNY.
    • The company is currently unprofitable, with a return on equity of -10.68% and a return on assets of -6.99%.
    • The company's liquidity position is moderate, with a current ratio of 0.87 and a debt-to-equity ratio of 0.32.
    • Analysts have a generally positive outlook, with a mean price target of 3.25 CNY and a mean recommendation of 2.25.
    • The company's revenue is concentrated in a single business segment, increasing its exposure to regional economic and regulatory risks.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$2,30
    Market cap
    HK$6.03B
    Enterprise valueⓘ
    HK$8.99B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    15.3x
    P / Bⓘ
    0.7x
    P / Tangible bookⓘ
    0.7x
    Tangible book
    HK$9.14B
    Net cashⓘ
    -HK$2.96B
    Current ratioⓘ
    0.9
    Debt / equityⓘ
    0.3
    ROAⓘ
    -7.0%
    ROEⓘ
    -10.7%
    Cash conversionⓘ
    -60.0%
    CapEx / revenueⓘ
    -10.0%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,09
    Predicted surprise
    0,00
    Beat probability
    45 %
    Analysts
    12
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-20 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate0,09
    Revenue—no estimate—no estimate3,0B CNY
    Operating income—no estimate—no estimate350,9M CNY
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution12 analysts
    Strong buy3
    Buy5
    Hold2
    Sell2
    Strong sell0
    12-month price targetHK$3,25 · Median HK$3,15
    Low HK$2,30High HK$4,57
    Operating income · consensus350,9M CNY
    EPS surprise
    −11,5 %
    reported vs consensus · miss
    Revenue surprise
    −10,6 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowHK$2,30
    MeanHK$3,25
    MedianHK$3,15
    HighHK$4,57
    SpotHK$2,30
    +41.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-34,9 %Bottom quartile
    Net Margin-36,9 %Bottom quartile
    ROE-10,7 %Bottom quartile
    Capex / Rev-10,0 %Below median
    D/E0,32Above median
    Cash Conv-0,60Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Jinxin Fertility Group Ltd Market data — financials · 2026-05-26
    • Jinxin Fertility Group Ltd Market data — analyst estimates · 2026-05-26
    • Jinxin Fertility Group Ltd Market data — ESG · 2026-05-26

    Ownership & reference

    Leadership

    • Yang DongChief Executive Officer, Executive Director
    • Yong ZhongExecutive Chairman of the Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    1951.HKCanonical
    HKEX · HKD

    Intel & risk

    PredictorBeat prob45 %Surprise0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage